Latest / The Biorevolution Podcast
More Boom or…Bust – What to expect from AI in biotech in 2025?
The biorevolution podcast #31
In some respects, 2024 has been a record year for AI in biotech, with the $1 billion founding of the antibody-centered biotech company Xaira and the awarding of the Nobel Prize in Chemistry to DeepMind researchers Demis Hassabis, John Jumper, and David Baker. However, despite years of investment and innovation, we still lack an answer to the most pressing question: Will AI revolutionize drug development, or are we in a bubble that is about to burst?
In episode 31 of the BioRevolution podcast, Andreas Horchler and Louise von Stechow explore various use cases for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.